Moderna (MRNA) – Investment Analysts’ Weekly Ratings Changes

Moderna (NASDAQ: MRNA) has recently received a number of price target changes and ratings updates:

• 5/4/2026 – Moderna had its price target raised by UBS Group AG from $36.00 to $45.00. They now have a “neutral” rating on the stock.
• 5/4/2026 – Moderna had its price target raised by Royal Bank Of Canada from $35.00 to $38.00. They now have a “sector perform” rating on the stock.
• 5/1/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $43.00 to $49.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Moderna was given a new $33.00 price target by Morgan Stanley.
• 4/2/2026 – Moderna had its price target raised by Barclays PLC from $25.00 to $48.00. They now have an “equal weight” rating on the stock.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the completion of the sale, the president directly owned 1,477,997 shares of the company’s stock, valued at approximately $71,535,054.80. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director directly owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 219,027 shares of company stock valued at $10,661,254. 10.80% of the stock is owned by corporate insiders.

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.